Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update
March 02, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Present at BIO CEO & Investor Digital Conference
February 10, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia
January 27, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
January 12, 2021 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
December 28, 2020 16:05 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement
December 23, 2020 08:39 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement
December 22, 2020 17:28 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
November 09, 2020 08:44 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors
November 05, 2020 09:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences to Present at Two Upcoming Investor Conferences
September 10, 2020 08:00 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...